A Study to Evaluate Chronic Hepatitis C Infection

PHASE3CompletedINTERVENTIONAL

Enrollment

636

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2014

Conditions

Chronic Hepatitis C Infection

Interventions

DRUG

ABT-450/r/ABT-267, ABT-333

ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet

DRUG

Ribavirin

Capsule (double-blind treatment period), tablet (open-label treatment period)

DRUG

Placebo for ABT-450/r/ABT-267

Tablet

DRUG

Placebo for ABT-333

Tablet

DRUG

Placebo for ribavirin

Capsule

All Listed Sponsors

lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT01716585 - A Study to Evaluate Chronic Hepatitis C Infection | Biotech Hunter | Biotech Hunter